Sucralfate, bismuth compounds, substituted benzimidazoles, trimipramine and pirenzepine in the short- and long-term treatment of duodenal ulcer.
D000535:Aluminum / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D000863:Antacids / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D001570:Benzodiazepinones / Q000009:adverse effects / Q000627:therapeutic use*; D001729:Bismuth / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003984:Dibenzazepines / Q000627:therapeutic use*; D004381:Duodenal Ulcer / Q000188:drug therapy*; D006801:Humans; D010890:Pirenzepine; D012008:Recurrence; D013392:Sucralfate; D013997:Time Factors; D014299:Trimipramine / Q000009:adverse effects / Q000627:therapeutic use*
D000863:Antacids; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D001570:Benzodiazepinones; D003984:Dibenzazepines; D010890:Pirenzepine; D013392:Sucralfate; D014299:Trimipramine; D000535:Aluminum; D001729:Bismuth